Legend Biotech Return on Tangible Equity 2019-2022 | LEGN

Current and historical return on tangible equity values for Legend Biotech (LEGN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Legend Biotech Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.35B $0.43B -95.33%
2021-12-31 $-0.39B $0.47B -126.47%
2021-09-30 $-0.36B $0.22B -137.72%
2021-06-30 $-0.30B $0.34B -103.83%
2021-03-31 $-0.34B $0.20B -112.45%
2020-12-31 $-0.30B $0.28B -144.08%
2020-09-30 $-0.31B $0.33B -279.28%
2020-06-30 $-0.27B $0.40B -985.45%
2020-03-31 $-0.17B $-0.17B 227.59%
2019-12-31 $-0.13B $-0.12B 432.52%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.612B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00